Pharmaceutical quality of inhalation and nasal products

Current effective version

PDF iconAdopted guideline

Currently under revision

Reference number CHMP/QWP/49313/2005
Published 21/06/2006
Effective from 01/10/2006
Keywords Inhalation, nasal, pharmaceutical quality, lung, pressurised metered dose inhalers, dry powder inhalers, products for nebulisation, non-pressurised metered dose inhalers, nasal sprays, nasal powders, nasal liquids
Description This document outlines expected quality aspects of human medicinal products intended for delivery of the active substance into the lungs, or to the nasal mucosa, with the purpose of evoking a local or systemic effect. These include pressurised metered dose inhalers, dry powder inhalers, products for nebulisation, and nonpressurised, metered dose inhalers, as well as pressurised metered dose nasal sprays, nasal powders, and nasal liquids.


Document history

Revision 1

In progress

PDF iconConcept paper

Published: 22/03/2017

 

Deadline for comments: 22/06/2017

First version

Current version

PDF iconAdopted guideline

In operation: 01/10/2006-present


Related content


How useful was this page?

Add your rating